GB2551453A - Nanocarrier delivery system for hydrophobic substances - Google Patents

Nanocarrier delivery system for hydrophobic substances

Info

Publication number
GB2551453A
GB2551453A GB1713495.8A GB201713495A GB2551453A GB 2551453 A GB2551453 A GB 2551453A GB 201713495 A GB201713495 A GB 201713495A GB 2551453 A GB2551453 A GB 2551453A
Authority
GB
United Kingdom
Prior art keywords
delivery system
hydrophobic substances
nanocarrier delivery
nanoparticles
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB1713495.8A
Other versions
GB201713495D0 (en
GB2551453B (en
Inventor
Yen Fu Ju
Meam Yee Tan Doryn
Nesaretnam Kalanthi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palm Oil Research and Development Board
Original Assignee
Palm Oil Research and Development Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palm Oil Research and Development Board filed Critical Palm Oil Research and Development Board
Publication of GB201713495D0 publication Critical patent/GB201713495D0/en
Publication of GB2551453A publication Critical patent/GB2551453A/en
Application granted granted Critical
Publication of GB2551453B publication Critical patent/GB2551453B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A nanocarrier delivery system for hydrophobic substances comprising a composition of nanoparticles. The nanoparticle comprises a surfactant of ascorbyl palmitate, a cholesterol, a hydrophilic polymer, a functionalized polymer containing a carboxylic end group, a chemical linker and a targeting protein. A method of producing the nanoparticles and the use of the nanoparticle for the manufacture of a pharmaceutical in the treatment and/or prevention of cancer and cancer related conditions.
GB1713495.8A 2015-01-23 2016-01-21 Nanocarrier delivery system for hydrophobic substances Active GB2551453B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI2015700198A MY197126A (en) 2015-01-23 2015-01-23 Nanocarrier delivery system for hydrophobic substances
PCT/MY2016/050004 WO2016118001A1 (en) 2015-01-23 2016-01-21 Nanocarrier delivery system for hydrophobic substances

Publications (3)

Publication Number Publication Date
GB201713495D0 GB201713495D0 (en) 2017-10-04
GB2551453A true GB2551453A (en) 2017-12-20
GB2551453B GB2551453B (en) 2020-09-09

Family

ID=56417447

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1713495.8A Active GB2551453B (en) 2015-01-23 2016-01-21 Nanocarrier delivery system for hydrophobic substances

Country Status (5)

Country Link
CN (1) CN107427471B (en)
AU (1) AU2016209724B2 (en)
GB (1) GB2551453B (en)
MY (1) MY197126A (en)
WO (1) WO2016118001A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094625A1 (en) * 2017-11-09 2019-05-16 Nexien Biopharma, Inc. Methods and compositions for parenteral administration of cannabidiol in the treatment of convulsive disorders
WO2020055929A1 (en) * 2018-09-11 2020-03-19 Memorial Sloan Kettering Cancer Center Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
CN112180079B (en) * 2020-09-25 2024-04-19 上海睿康生物科技有限公司 Stable liposome particle and application thereof in immune turbidimetry detection
CN113318217A (en) * 2021-06-02 2021-08-31 厦门大学 BTZ-TPGS compound, nano preparation, preparation and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053407A1 (en) * 2001-12-19 2003-07-03 Research Development Foundation Liposomal delivery of vitamin e based compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101569607B (en) * 2009-06-16 2011-02-16 中国药科大学 Di-demethoxycurcumin precursor liposome and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053407A1 (en) * 2001-12-19 2003-07-03 Research Development Foundation Liposomal delivery of vitamin e based compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FU J.Y et al., "Tumor Regression After Systemic Administration of Tocotrienol Entrapped in Tumor-Targeted Vesicles", Journal of Controlled Release, (20090000), vol. 140, pages 95 - 99, *
FU J.Y. et al., "Novel Tocotrienol-Entrapping Vesicles can Eradicate Solid Tumors After Intravenous Administration", Journal of Controlled Release, (20110000), vol. 154, pages 20 - 26, *
FU J.Y. et al., "Tumor-Targeted Niosome as Novel Carrier for Intravenous Administration of Tocotrienol", Asian Journal of Pharmaceutical Sciences, vol. 11, (20160000), pages 79 - 80, (20151125), *
GOPINATH D. et al., "Ascorbyl Palmitate Vesciles (Aspasomes): Formation, Characterization and Applications", International Journal of Pharmaceutics, (20040000), vol. 271, pages 95 - 113, *
VARSHOSAZ J. et al., "Niosomes of Ascorbic Acid and a-Tocopherol in the Cerebral Ishemia-Reperfusion Model in Male Rats", BioMed Research International, (20140000), vol. 2014, no. art. ID 816103, *

Also Published As

Publication number Publication date
CN107427471A (en) 2017-12-01
AU2016209724B2 (en) 2021-03-11
WO2016118001A1 (en) 2016-07-28
GB201713495D0 (en) 2017-10-04
AU2016209724A1 (en) 2017-09-14
GB2551453B (en) 2020-09-09
CN107427471B (en) 2020-07-31
MY197126A (en) 2023-05-26

Similar Documents

Publication Publication Date Title
PH12017500023A1 (en) Targeted conjugates and particles and formulations thereof
MY172519A (en) Solid polymeric controlled release nanoparticle
MX350589B (en) Functional pla-peg copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging.
PH12015501486A1 (en) Nanoparticle compositions of albumin and paclitaxel
GB2551453A (en) Nanocarrier delivery system for hydrophobic substances
WO2010083337A3 (en) Composite nanostructures and methods for making and using them
EP3463316A4 (en) Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use
WO2014057432A3 (en) Multicomponent lipid nanoparticles and processes for the preparation thereof
WO2015123576A3 (en) Targeted nanoparticle compositions and methods of their use to treat obesity
IN2015DN03219A (en)
WO2010131907A3 (en) Sirna delivery system using self-assembled polymeric nanoparticles
WO2014052935A3 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
WO2013028942A8 (en) Targeting microbubbles
WO2015152693A3 (en) Novel double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases
WO2011143201A3 (en) Ratiometric combinatorial drug delivery
WO2010135418A3 (en) Implantable medical devices for therapeutic agent delivery
PH12018500449A1 (en) Polymeric bile acid nanocompositions targeting the pancreas and colon
WO2014089247A3 (en) Modular polymer hydrogel nanoparticles and methods of their manufacture
PH12017502155A1 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
EP3518939A4 (en) Functional rna and small-molecule drug therapeutic complexes and nanoparticle delivery vehicles
WO2015153805A3 (en) Targeted polymerized nanoparticles for cancer treatment
PH12016500565A1 (en) Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
WO2012040331A3 (en) Multistage nanoparticles
WO2018229093A8 (en) Nanoparticles as delivery vehicles of active ingredients and methods for the production thereof
MX2014012271A (en) Bis-polymer lipid-peptide conjugates and nanoparticles thereof.